CAS 156586-89-9
:Edrecolomab
Description:
Edrecolomab, also known as the monoclonal antibody 17-1A, is a therapeutic agent primarily used in the treatment of colorectal cancer. It is designed to target the epithelial cell adhesion molecule (EpCAM), which is overexpressed in many epithelial tumors, including colorectal cancer. This targeting mechanism allows Edrecolomab to facilitate the immune system's ability to recognize and destroy cancer cells. The substance is characterized by its specificity for EpCAM, which contributes to its potential efficacy in tumor targeting while minimizing effects on normal tissues. Edrecolomab is administered via injection and has been studied in various clinical settings, often in combination with other therapies. Its development reflects a broader trend in oncology towards targeted therapies that leverage the body's immune response. As with many monoclonal antibodies, potential side effects may include infusion reactions and immune-related adverse events, necessitating careful monitoring during treatment. Overall, Edrecolomab represents a significant advancement in the targeted treatment of colorectal cancer.
Formula:Unspecified
Synonyms:- Immunoglobulin G2a, anti-(human colon cancer tumor-associated antigen) (mouse monoclonal 17-1A γ2a-chain), disulfide with mouse monoclonal 17-1A light chain, dimer
- C 1
- Panorex
- Edrecolomab
- Immunoglobulin G 2a (mouse monoclonal 17-1A γ-chain anti-human colon cancer tumor-associated antigen), disulfide with mouse monoclonal 17-1A light chain, dimer
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 3 products.
Edrecolomab
CAS:Edrecolomab (Panorex) is a mouse-derived antibody targeting cell surface glycoprotein 17-1A, with antitumor activity.Purity:95%Color and Shape:LiquidMolecular weight:144.18 kDa
